Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial.
Cytryn SL, Moy RH, Cowzer D, Shah RH, Chou JF, Joshi SS, Ku GY, Maron SB, Desai A, Yang J, Sugarman R, Rao D, Goldberg Z, Charalambous C, Lapshina M, Antoine A, Socolow F, Trivedi N, Capanu M, Gerdes H, Schattner MA, Simmons M, Lacouture ME, Paroder V, Tang LH, Shia J, Ilson DH, Solit DB, Berger MF, Janjigian YY. Cytryn SL, et al. Among authors: cowzer d. Lancet Oncol. 2023 Oct;24(10):1073-1082. doi: 10.1016/S1470-2045(23)00358-3. Epub 2023 Sep 1. Lancet Oncol. 2023. PMID: 37666264 Clinical Trial.
Emerging RAS-directed therapies for cancer.
Conroy M, Cowzer D, Kolch W, Duffy AG. Conroy M, et al. Among authors: cowzer d. Cancer Drug Resist. 2021 Apr 8;4(3):543-558. doi: 10.20517/cdr.2021.07. eCollection 2021. Cancer Drug Resist. 2021. PMID: 35582302 Free PMC article. Review.
ATM Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic Implications.
El Jabbour T, Misyura M, Cowzer D, Zimmermann M, Rimkunas V, Marra A, Derakhshan F, Selenica P, Parilla M, Setton JS, Ceyhan-Birsoy O, Kemel Y, Catchings A, Ranganathan M, Ku GY, Janjigian YY, Zinda M, Koehler M, Stadler Z, Shia J, Reis-Filho JS, Mandelker D. El Jabbour T, et al. Among authors: cowzer d. J Natl Cancer Inst. 2022 May 9;114(5):761-770. doi: 10.1093/jnci/djac024. J Natl Cancer Inst. 2022. PMID: 35078243 Free PMC article.
Outcomes and Molecular Features of Brain Metastasis in Gastroesophageal Adenocarcinoma.
Tsai C, Nguyen B, Luthra A, Chou JF, Feder L, Tang LH, Strong VE, Molena D, Jones DR, Coit DG, Ilson DH, Ku GY, Cowzer D, Cadley J, Capanu M, Schultz N, Beal K, Moss NS, Janjigian YY, Maron SB. Tsai C, et al. Among authors: cowzer d. JAMA Netw Open. 2022 Aug 1;5(8):e2228083. doi: 10.1001/jamanetworkopen.2022.28083. JAMA Netw Open. 2022. PMID: 36001319 Free PMC article.
Durvalumab and PET-Directed Chemoradiation in Locally Advanced Esophageal Adenocarcinoma: A Phase Ib/II Study.
Cowzer D, Wu AJ, Sihag S, Walch HS, Park BJ, Jones DR, Gu P, Maron SB, Sugarman R, Chalasani SB, Shcherba M, Capanu M, Chou JF, Choe JK, Nosov A, Adusumilli PS, Yeh R, Tang LH, Ilson DH, Janjigian YY, Molena D, Ku GY. Cowzer D, et al. Ann Surg. 2023 Sep 1;278(3):e511-e518. doi: 10.1097/SLA.0000000000005818. Epub 2023 Feb 10. Ann Surg. 2023. PMID: 36762546 Clinical Trial.
Outcomes and a prognostic classifier in patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockade.
Randon G, Aoki Y, Cohen R, Provenzano L, Nasca V, Klempner SJ, Maron SB, Cerantola R, Chao J, Fornaro L, Ferrari Bravo W, Ghelardi F, Ambrosini M, Manca P, Salati M, Kawazoe A, Zhu V, Cowzer D, Genovesi V, Lonardi S, Shitara K, André T, Pietrantonio F. Randon G, et al. Among authors: cowzer d. J Immunother Cancer. 2023 Jun;11(6):e007104. doi: 10.1136/jitc-2023-007104. J Immunother Cancer. 2023. PMID: 37277193 Free PMC article.
22 results